EPO and myeloproliferative neoplasm: For example, it was used to assess whether polycythemia was associated or not with high EPO levels, i.e., whether it was due to forms, possibly inherited, of dysregulated EPO production or to cell-autonomous activation of erythroid differentiation by somatic driver mutations such as those found in the myeloproliferative neoplasm Polycythemia Vera [10].